Meredith E. Adams

Meredith E. Adams

Auto-generated profile, based on publicly available information

Meredith E. Adams

Department of Otolaryngology‐Head & Neck Surgery University of Minnesota Minneapolis Minnesota USA

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 April 2020 in Otolaryngology–Head and Neck Surgery
Verified
Journal Article
Open access
PDF file
GBGregory J. Basura
Gregory J. Basura
MAMeredith E. Adams
Meredith E. Adams
AMAshkan Monfared
Ashkan Monfared
SSSeth R. Schwartz
Seth R. Schwartz
PAPatrick J. Antonelli
Patrick J. Antonelli
EBErin M. Buchanan
Erin M. Buchanan
Objective: Ménière’s disease (MD) is a clinical condition defined by spontaneous vertigo attacks (each lasting 20 minutes to 12 hours) with documented low‐ to midfrequency sensorineural hearing loss in the affected ear before, during, or after one of the episodes of vertigo. It also presents with fluctuating aural symptoms (hearing loss, tinnitus, or ear fullness) in the affected ear. The underlying etiology of MD is not completely clear, yet it has been associated with inner ear fluid (endolymph) volume increases, culminating in episodic ear symptoms (vertigo, fluctuating hearing loss, tinnitus, and aural fullness). Physical examination findings are often unremarkable, and audiometric testing may or may not show low‐ to midfrequency sensorineural hearing loss. Conventional imaging, if performed, is also typically normal. The goals of MD treatment are to prevent or reduce vertigo severity and frequency; relieve or prevent hearing loss, tinnitus, and aural fullness; and improve quality of life. Treatment approaches to MD are many and typically include modifications of lifestyle factors (eg, diet) and medical, surgical, or a combination of therapies.Purpose: The primary purpose of this clinical practice guideline is to improve the quality of the diagnostic workup and treatment outcomes of MD. To achieve this purpose, the goals of this guideline are to use the best available published scientific and/or clinical evidence to enhance diagnostic accuracy and appropriate therapeutic interventions (medical and surgical) while reducing unindicated diagnostic testing and/or imaging.

1 November 2007 in JAMA Otolaryngology–Head & Neck Surgery
Verified
Journal Article
Closed access
PDF file
MPMelissa A. Pynnonen
Melissa A. Pynnonen
SMShraddha S. Mukerji
Shraddha S. Mukerji
HKH. Myra Kim
H. Myra Kim
MAMeredith E. Adams
Meredith E. Adams
JTJeffrey E. Terrell
Jeffrey E. Terrell
Research from JAMA Otolaryngology–Head & Neck Surgery — Nasal Saline for Chronic Sinonasal Symptoms — A Randomized Controlled Trial

28 February 2007 in Mammalian Genome
Verified
Journal Article
Closed access
PDF file
EHElizabeth A. Hurd
Elizabeth A. Hurd
PCPatrice L. Capers
Patrice L. Capers
MBMarsha N. Blauwkamp
Marsha N. Blauwkamp
MAMeredith E. Adams
Meredith E. Adams
YRYehoash Raphael
Yehoash Raphael
DMDonna Martin
Donna Martin

8 April 2020 in Otolaryngology–Head and Neck Surgery
Verified
Journal Article
Open access
PDF file
GBGregory J. Basura
Gregory J. Basura
MAMeredith E. Adams
Meredith E. Adams
AMAshkan Monfared
Ashkan Monfared
SSSeth R. Schwartz
Seth R. Schwartz
PAPatrick J. Antonelli
Patrick J. Antonelli
EBErin M. Buchanan
Erin M. Buchanan
Objective: Ménière’s disease (MD) is a clinical condition defined by spontaneous vertigo attacks (each lasting 20 minutes to 12 hours) with documented low‐ to midfrequency sensorineural hearing loss in the affected ear before, during, or after one of the episodes of vertigo. It also presents with fluctuating aural symptoms (hearing loss, tinnitus, or ear fullness) in the affected ear. The underlying etiology of MD is not completely clear, yet it has been associated with inner ear fluid volume increases, culminating in episodic ear symptoms (vertigo, fluctuating hearing loss, tinnitus, and aural fullness). Physical examination findings are often unremarkable, and audiometric testing may or may not show low‐ to midfrequency sensorineural hearing loss. Imaging, if performed, is also typically normal. The goals of MD treatment are to prevent or reduce vertigo severity and frequency; relieve or prevent hearing loss, tinnitus, and aural fullness; and improve quality of life. Treatment approaches to MD are many, and approaches typically include modifications of lifestyle factors (eg, diet) and medical, surgical, or a combination of therapies.Purpose: The primary purpose of this clinical practice guideline is to improve the quality of the diagnostic workup and treatment outcomes of MD. To achieve this purpose, the goals of this guideline are to use the best available published scientific and/or clinical evidence to enhance diagnostic accuracy and appropriate therapeutic interventions (medical and surgical) while reducing unindicated diagnostic testing and/or imaging.

1 January 2009 in Otology & Neurotology
Verified
Journal Article
Closed access
HAH. Alexander Arts
H. Alexander Arts
MAMeredith E. Adams
Meredith E. Adams
STSteven A. Telian
Steven A. Telian
HEHussam El-Kashlan
Hussam El-Kashlan
PKPaul R. Kileny
Paul R. Kileny
Objective: Electrocochleography (ECoG) is often used in the evaluation of episodic vertigo, and abnormal findings are commonly thought to be due to endolymphatic hydrops. We have observed that a number of patients with abnormal ECoG were ultimately found to have superior semicircular canal dehiscence (SSCD). Therefore, we examined the electrocochleographic findings in a series of patients with documented SSCD. Study Design: Retrospective case series. Setting: Academic medical center. Patients: Seven adult patients with unilateral SSCD and 4 patients with bilateral SSCD who underwent tympanic ECoG as part of a diagnostic or preoperative evaluation that also included vestibular-evoked myogenic potentials (VEMPs). Interventions: Patients underwent audiometric testing, ECoG, VEMP, and high-resolution temporal bone computed tomography reformatted to optimally view the superior semicircular canal. Five patients underwent superior canal obliteration. Postoperative VEMP and ECoG were performed in 4 of these patients. Intraoperative continuous ECoG was performed in 1 patient. Main Outcome Measures: Summating potential to action potential (SP/AP) ratio on ECoG. Results: Fourteen of 15 ears confirmed to have SSCD on computed tomographic imaging were found to have an elevated SP/AP ratio (defined as >0.40). In one patient with bilateral SSCD, the ear with the radiographically less severe dehiscence had an SP/AP ratio of 0.40, at the upper limit of normal, and a normal VEMP threshold. In all 4 patients who underwent obliteration of the dehiscent canal, and for whom postoperative test results were available, the SP/AP ratio normalized in the operated ear. In the 1 patient who underwent intraoperative ECoG, the SP/AP ratio normalized immediately after canal occlusion. Conclusion: An elevated SP/AP ratio seems to be a consistent finding in SSCD syndrome and, like the other abnormal audiometric and electrophysiologic findings associated with the syndrome, normalizes after surgical correction. Elevation of the SP/AP ratio has historically been associated with endolymphatic hydrops. The present findings expand the differential diagnosis of an abnormal ECoG and may shed light on the origin of an elevated summating potential.

17 April 2018 in Otolaryngology–Head and Neck Surgery
Verified
Journal Article
Closed access
EKElizabeth Kelly
Elizabeth Kelly
BLBin Li
Bin Li
MAMeredith E. Adams
Meredith E. Adams